Enzolytics Stock Performance
| ENZC Stock | USD 0.0007 0.0001 16.67% |
Enzolytics holds a performance score of 7 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -0.55, which means possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Enzolytics are expected to decrease at a much lower rate. During the bear market, Enzolytics is likely to outperform the market. Use Enzolytics potential upside and the relationship between the skewness and relative strength index , to analyze future returns on Enzolytics.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Enzolytics are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of rather inconsistent basic indicators, Enzolytics exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
| Total Cashflows From Investing Activities | -5 M |
Enzolytics |
Enzolytics Relative Risk vs. Return Landscape
If you would invest 0.06 in Enzolytics on April 25, 2025 and sell it today you would earn a total of 0.01 from holding Enzolytics or generate 16.67% return on investment over 90 days. Enzolytics is currently generating 1.4045% in daily expected returns and assumes 15.7679% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Enzolytics, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Enzolytics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Enzolytics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Enzolytics, and traders can use it to determine the average amount a Enzolytics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0891
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ENZC | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 15.77 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.4 actual daily | 28 72% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 7 93% of assets perform better |
Based on monthly moving average Enzolytics is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Enzolytics by adding it to a well-diversified portfolio.
Enzolytics Fundamentals Growth
Enzolytics Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Enzolytics, and Enzolytics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Enzolytics Pink Sheet performance.
| Return On Asset | -7.05 | |||
| Operating Margin | (19.24) % | |||
| Current Valuation | 71.57 M | |||
| Shares Outstanding | 2.44 B | |||
| Price To Sales | 2,083 X | |||
| Revenue | 190 K | |||
| EBITDA | (886.77 K) | |||
| Cash And Equivalents | 5.76 K | |||
| Total Debt | 233.12 K | |||
| Book Value Per Share | (0.63) X | |||
| Cash Flow From Operations | 4.89 M | |||
| Earnings Per Share | (4.76) X | |||
| Total Asset | 3.31 M | |||
About Enzolytics Performance
By analyzing Enzolytics' fundamental ratios, stakeholders can gain valuable insights into Enzolytics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Enzolytics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Enzolytics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Enzolytics, Inc., a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. In addition, it has created a proprietary cell line that produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about Enzolytics performance evaluation
Checking the ongoing alerts about Enzolytics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Enzolytics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Enzolytics is way too risky over 90 days horizon | |
| Enzolytics has some characteristics of a very speculative penny stock | |
| Enzolytics appears to be risky and price may revert if volatility continues | |
| Enzolytics has high likelihood to experience some financial distress in the next 2 years | |
| Enzolytics currently holds 233.12 K in liabilities. Enzolytics has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Enzolytics until it has trouble settling it off, either with new capital or with free cash flow. So, Enzolytics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Enzolytics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Enzolytics to invest in growth at high rates of return. When we think about Enzolytics' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 190 K. Net Loss for the year was (57.28 K) with profit before overhead, payroll, taxes, and interest of 52.81 K. |
- Analyzing Enzolytics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Enzolytics' stock is overvalued or undervalued compared to its peers.
- Examining Enzolytics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Enzolytics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Enzolytics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Enzolytics' pink sheet. These opinions can provide insight into Enzolytics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Enzolytics Pink Sheet analysis
When running Enzolytics' price analysis, check to measure Enzolytics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enzolytics is operating at the current time. Most of Enzolytics' value examination focuses on studying past and present price action to predict the probability of Enzolytics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enzolytics' price. Additionally, you may evaluate how the addition of Enzolytics to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Stocks Directory Find actively traded stocks across global markets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |